hC Bioscience Presents Preclinical Data at ASGCT Showing Strong Potential in Hemophilia A Using tRNA-based Protein Editing Platform

BOSTON--(BUSINESS WIRE)--hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today presented preclinical data supporting its lead program in severe hemophilia A at the American Society of Gene and Cell Therapy Annual Meeting in Baltimore, Md. Suchul Jang, Ph.D., Senior Director, Biology, presented data demonstrating that HCB-101, an anticodon engineered (ACE) tRNA, restores production of full-lengt